EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial

Wen Zhang, Cai-Feng Gong, Jing-Long Huang, Tian-Yi Liu, Yong-Kun Sun, Zhi-Chao Jiang, Wang Qu, Lin Yang, Ying Xin, Fei-Long Zhao, Yue-Zong Bai, Ai-Ping Zhou

Cancer Immunology, Immunotherapy · 20.11.2025 · 74 (12)

DOI: 10.1007/s00262-025-04237-3 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 20.11.2025. Verfasst von Wen Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Hope Run Special Fund of Cancer Foundation of China, Beijing Natural Science Foundation, Major Project/Translational research project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabAntibodies, Monoclonal, HumanizedQuinazolinesHumansFemaleMaleMiddle AgedAgedAdultDNA Mismatch RepairNeoplasm MetastasisAged, 80 and overDrug Resistance, NeoplasmBenzofurans

Stichwörter der Autor:innen

AlbuminColorectal cancerImmune checkpoint inhibitorLiver metastasisNeutrophil-to-lymphocyte ratioTyrosine kinase inhibitor

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedsintilimabQuinazolinesHMPL-013Benzofurans

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Medical Department, 3D Medicines Inc., Shanghai, 201114, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. aiping_z…

Förderung

  • Beijing Hope Run Special Fund of Cancer Foundation of China
  • Beijing Natural Science Foundation
  • Major Project/Translational research project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences
  • CAMS Innovation Fund for Medical Sciences (CIFMS)

Zitieren

APA

Zhang, W., Gong, C. F., Huang, J. L., Liu, T. Y., Sun, Y. K., Jiang, Z. C., Qu, W., Yang, L., Xin, Y., Zhao, F. L., Bai, Y. Z., & Zhou, A. P. (2025). Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial. Cancer Immunology, Immunotherapy, 74(12). https://doi.org/10.1007/s00262-025-04237-3

Vancouver

Zhang W, Gong CF, Huang JL, Liu TY, Sun YK, Jiang ZC, et al. Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial. Cancer Immunology, Immunotherapy. 2025;74(12). doi:10.1007/s00262-025-04237-3

BibTeX
@article{Zhang2025,
  author = {Zhang, Wen and Gong, Cai-Feng and Huang, Jing-Long and Liu, Tian-Yi and Sun, Yong-Kun and Jiang, Zhi-Chao and Qu, Wang and Yang, Lin and Xin, Ying and Zhao, Fei-Long and Bai, Yue-Zong and Zhou, Ai-Ping},
  title = {Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {12},
  doi = {10.1007/s00262-025-04237-3}
}
Kostenlos starten →